Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

TSX:GUD - Post Discussion

Knight Therapeutics Inc > Expectations for next Q results are low
View:
Post by Snowballgrowth on Feb 19, 2023 5:41pm

Expectations for next Q results are low

Expectations are very low and investors are now impatient. Let see, next results should available in a month or so.

At least Tafasitamab had been submitted for regulatory review in Brazil..
Comment by Chianchin on Feb 21, 2023 2:51pm
I will start buying at $2.50
Comment by wofats on Feb 22, 2023 2:24pm
WHY?
Comment by EbbFlow88 on Feb 23, 2023 8:49am
I think those two things have been true for a while now lol.. low expectations and impatience.  There will likely be some mark to market losses in the funds ending 2022, which will probably rebound in Q1. We'll see how March plays out. Operations should be pretty steady. Not expecting anything major in Q4. I'd like to see that Exelon is pretty well fully integrated and they are done ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities